Review article: Coagulation disorders in chronic liver disease

Alimentary Pharmacology and Therapeutics

Volumn 26, Issue SUPPL. 1, 2007, Pages 21-28

  Peck Radosavljevic, M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR; FIBRINOLYTIC AGENT; PROCOAGULANT; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR;

ANTICOAGULATION; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CHRONIC LIVER DISEASE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; FIBRINOLYSIS; HEMOSTASIS; HUMAN; LIVER CIRRHOSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVIEW; RISK ASSESSMENT; THROMBOCYTE ACTIVATION; THROMBOCYTE DYSFUNCTION; THROMBOCYTOPENIA; THROMBOSIS;

EID: 35448929752     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03509.x     Document Type: Review

References (45)

1. Amitrano L, Guardascione MA, Brancaccio V, Balzano A. Coagulation disorders in liver disease. Semin Liver Dis 2002 22 : 83 96.
2. Andrews RK, Berndt MC. Platelet physiology and thrombosis. Thromb Res 2004 114 : 447 53.
3. Kujovich JL. Hemostatic defects in end stage liver disease. Crit Care Clin 2005 21 : 563 87.
4. McCormick PA, Murphy KM. Splenomegaly, hypersplenism and coagulation abnormalities in liver disease. Baillière's Clin Gastroenterol 2000 14 : 1009 31.
5. Rodríguez-Iñigo E, Bartolomé J, Quiroga JA, et al. Expression of factor VII in the liver of patients with liver disease: correlations with the disease severity and impairment in the hemostasis. Blood Coagul Fibrinolysis 2001 12 : 193 9.
6. Tacke F, Fiedler K, von Depka M, et al. Clinical and prognostic role of plasma coagulation factor XIII activity for bleeding disorders and 6-year survival in patients with chronic liver disease. Liver Int 2006 26 : 173 81.
7. Green G, Poller L, Thomson JM, Dymock IW. Factor VII as a marker of hepatocellular synthetic function in liver disease. J Clin Path 1976 29 : 971 5.
8. Deitcher SR. Interpretation of the international normalised ratio in patients with liver disease. Lancet 2002 359 : 47 8.
9. Bernstein DE, Jeffers L, Erhardtsen E, et al. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology 1997 113 : 1930 7.
10. Violi F, Ferro D, Basili S, et al. Prognostic value of clotting and fibrinolytic systems in a follow-up of 165 liver cirrhotic patients. CALC Group. Hepatology 1995 22 : 96 100.
11. Kerr R. New insights into haemostasis in liver failure. Blood Coagul Fibrinolysis 2003 14 (Suppl. 1 S43 5.
12. Hollestelle MJ, Geertzen HG, Straatsburg IH, van Gulik TM, van Mourik JA. Factor VIII expression in liver disease. Thromb Haemost 2004 91 : 267 75.
13. Do H, Healey JF, Waller EK, Lollar P. Expression of Factor VIII by murine liver sinusoidal endothelial cells. J Biol Chem 1999 274 : 19587 92.
14. Sarafanov AG, Ananyeva NM, Shima M, Saenko EL. Cell surface heparan sulfate proteoglycans participate in Factor VIII catabolism mediated by low density lipoprotein receptor-related protein. J Biol Chem 2001 276 : 11970 9.
15. Francis JL, Armstrong DJ. Acquired dysfibrinogenaemia in liver disease. J Clin Pathol 1982 35 : 667 72.
16. Palascak JE, Martinez J. Dysfibrinogenemia associated with liver disease. J Clin Invest 1977 60 : 89 95.
17. Tripodi A, Salerno F, Chantarangkul V, et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005 41 : 553 8.
18. Colucci M, Binetti BM, Branca MG, et al. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. Hepatology 2003 38 : 230 7.
19. Leebeek FW, Kluft C, Knot EA, de Maat MP, Wilson JH. A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis. Gastroenterology 1991 101 : 1382 90.
20. Van Thiel DH, George M, Fareed J. Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease. Thromb Haemost 2001 85 : 667 70.
21. Hu K-Q, Yu AS, Tiyyagura L, Redeker AG, Reynolds TB. Hyperfibrinolytic activity in hospitalized cirrhotic patients in a referral liver unit. Am J Gastroenterol 2001 96 : 1581 6.
22. Stricker RB, Wong D, Shiu DT, Reyes PT, Shuman MA. Activation of plasminogen by tissue plasminogen activator on normal and thrombasthenic platelets: effects on surface proteins and platelet aggregation. Blood 1986 68 : 275 80.
23. Loscalzo J, Vaughan DE. Tissue plasminogen activator promotes platelet disaggregation in plasma. J Clin Invest 1987 79 : 1749 55.
24. Violi F, Basili S, Ferro D, Quintarelli C, Alessandril C, Cordova C. Association between high values of D-dimer and tissue-plasminogen activator activity and first gastrointestinal bleeding in cirrhotic patients. CALC Group. Thromb Haemost 1996 76 : 177 83.
25. Agarwal S, Joyner KA Jr., Swaim MW. Ascites fluid as a possible origin for hyperfibrinolysis in advanced liver disease. Am J Gastroenterol 2000 95 : 3218 24.
26. Peck-Radosavljevic M. Thrombocytopenia in liver disease. Can J Gastroenterol 2000 14 (Suppl. D 60D 6D.
27. Aster RH. Pooling of platelets in the spleen: role in the pathogenesis of "hypersplenic" thrombocytopenia. J Clin Invest 1966 45 : 645 57.
28. Peck-Radosavljevic M, Zacherl J, Meng YG, et al. Is inadequate Thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver? J Hepatol 1997 27 : 127 31.
29. Goulis J, Chau TN, Jordan S, et al. Thrombopoietin concentrations are low in patients with cirrhosis and thrombocytopenia and are restored after orthotopic liver transplantation. Gut 1999 44 : 754 8.
30. Iga D, Tomimatsu M, Endo H, Ohkawa S-I, Yamada O. Improvement of thrombocytopenia with disappearance of HCV RNA in patients treated by interferon-α therapy: possible etiology of HCV-associated immune thrombocytopenia. Eur J Haematol 2005 75 : 417 23.
31. Kajihara M, Kato S, Okazaki Y, et al. A role of autoantibody-mediated platelet destruction in thrombocytopenia in patients with cirrhosis. Hepatology 2003 37 : 1267 76.
32. Doi T, Homma H, Mezawa S, et al. Mechanisms for increment of platelet associated IgG and platelet surface IgG and their implications in immune thrombocytopenia associated with chronic viral liver disease. Hepatol Res 2002 24 : 23 33.
33. Escolar G, Cases A, Viñas M, et al. Evaluation of acquired platelet dysfunctions in uremic and cirrhotic patients using the platelet function analyzer (PFA-100™): influence of hematocrit elevation. Haematologica 1999 84 : 614 9.
34. Laffi G, Marra F, Gresele P, et al. Evidence for a storage pool defect in platelets from cirrhotic patients with defective aggregation. Gastroenterology 1992 103 : 641 6.
35. Laffi G, Cominelli F, Ruggiero M, et al. Altered platelet function in cirrhosis of the liver: impairment of inositol lipid and arachidonic acid metabolism in response to agonists. Hepatology 1988 8 : 1620 6.
36. Ordinas A, Escolar G, Cirera I, et al. Existence of a platelet-adhesion defect in patients with cirrhosis independent of hematocrit: studies under flow conditions. Hepatology 1996 24 : 1137 42.
37. Laffi G, Marra F, Failli P, et al. Defective signal transduction in platelets from cirrhotics is associated with increased cyclic nucleotides. Gastroenterology 1993 105 : 148 56.
38. Sanchez-Roig MJ, Rivera J, Moraleda JM, Garcia VV. Quantitative defect of glycoprotein Ib in severe cirrhotic patients. Am J Hematol 1994 45 : 10 5.
39. Jackson SP, Nesbitt WS, Kulkarni S. Signaling events underlying thrombus formation. J Thromb Haemost 2003 1 : 1602 12.
40. Levi M, ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999 341 : 586 93.
41. Joist JH. AICF and DIC in liver cirrhosis: expressions of a hypercoagulable state. Am J Gastroenterol 1999 94 : 2801 3.
42. Ben-Ari Z, Osman E, Hutton RA, Burroughs AK. Disseminated intravascular coagulation in liver cirrhosis: fact or fiction? Am J Gastroenterol 1999 94 : 2977 82.
43. Vukovich T, Teufelsbauer H, Fritzer M, Kreuzer S, Knoflach P. Hemostasis activation in patients with liver cirrhosis. Thromb Res 1995 77 : 271 8.
44. Amitrano L, Guardascione MA, Brancaccio V, et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol 2004 40 : 736 41.
45. Gómez MR, García ES, Lacomba DL, Marchante I, Grande L, Fernandez MC. Antiphospholipid antibodies are related to portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol 2000 31 : 237 40.